Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Oct 13, 2026
Biodexa Pharmaceuticals filed Prospectus Supplement No. 5 to its F-1 resale prospectus, incorporating its October 8, 2026 Form 6-K. The supplement relates to the resale by selling shareholders of up to 10,950 ordinary shares represented by 219 American Depositary Shares. The embedded 6-K announces a mandatory ADS ratio change from one ADS per 50 ordinary shares to one ADS per 400 ordinary shares, effective on or about October 26, 2026.
Key figures
- New ratio
- 1 ADS : 400 ordinary shares
- Old ratio
- 1 ADS : 50 ordinary shares
- Price date
- October 12, 2026
- Effective date
- on or about October 26, 2026
- Last closing price
- 0.3832
- Reverse split ratio
- 1-for-8 (old ADSs to new ADSs)
- Ads resale ads count
- 219
- Ads resale shares ordinary
- 10950
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.